Jul 23, 2025 07:19AM Maxim Group Downgrades Brainstorm Cell Therapeutics (BCLI) to Hold

Jul 17, 2025 04:31PM BrainStorm Cell Therapeutics delisted from NASDAQ, moves to OTCQB

Jul 8, 2025 07:01AM FDA to review citizen petition on BrainStorm's (BCLI) NurOwn ALS treatment data

Jun 25, 2025 04:42PM Brainstorm Cell Therapeutics (BCLI) Files for 2.76M Share Offering by Selling Stockholders

May 27, 2025 07:04AM Brainstorm Cell Therapeutics (BCLI) Secures Manufacturing Partnership with Minaris

May 19, 2025 07:01AM Brainstorm Cell Therapeutics (BCLI) Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn for ALS

May 15, 2025 06:43PM Brainstorm Cell Therapeutics (BCLI) Misses Q1 EPS by 45c

Apr 10, 2025 07:30AM Brainstorm Cell Therapeutics (BCLI) Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn in ALS

Mar 26, 2025 08:15AM Brainstorm Cell Therapeutics (BCLI) Granted Compliance Extension from Nasdaq

Dec 30, 2024 08:00AM Brainstorm Cell Therapeutics (BCLI) Issues 2024 Letter to Shareholders

Dec 3, 2024 07:05AM Brainstorm Cell Therapeutics (BCLI) Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology

Nov 14, 2024 09:34PM Brainstorm Cell Therapeutics (BCLI) Misses Q3 EPS by 176c

Oct 30, 2024 07:58AM Brainstorm Cell Therapeutics (BCLI) PT Lowered to $10 at Maxim Group

Oct 30, 2024 06:01AM Brainstorm Cell Therapeutics (BCLI) Regains Nasdaq Compliance

Sep 24, 2024 04:32PM Brainstorm Cell Therapeutics (BCLI) Files for 16.67M Share Offering by Selling Stockholders

Aug 14, 2024 08:02AM Brainstorm Cell Therapeutics (BCLI) Tops Q2 EPS by 3c

Jun 27, 2024 09:15AM Brainstorm Cell Therapeutics (BCLI) Prices 11.11M Share Offering at $0.36/sh

Jun 26, 2024 08:02AM Brainstorm Cell Therapeutics (BCLI) Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn Clinical Trial

Jun 20, 2024 06:01AM Brainstorm Cell Therapeutics (BCLI) Appoints Haro Hartounian as COO